摘要
天疱疮是一种自身免疫性水疱性疾病,主要累及皮肤和黏膜,严重时可导致患者死亡。重症天疱疮患者以往首选长期大剂量糖皮质类固醇激素联合或不联合免疫抑制剂治疗,但有些患者在使用糖皮质类固醇激素后可出现严重副作用。利妥昔单抗作为一种单克隆抗CD20抗体,近年来已被用于治疗顽固重症天疱疮患者,并取得满意疗效。
Pemphigus is a life-threatening autoimmune blistering disease affecting the skin and mucosa.Patients with severe pemphigus require long-term treatment with corticosteroids and other immunosuppressive drugs,which can lead to serious adverse events.Rituximab,a monoclonal antibody directed against the CD20 antigen of B lymphocytes,has been demonstrated to be effective in recalcitrant and life-threatening pemphigus.
出处
《中国医学科学院学报》
CAS
CSCD
北大核心
2009年第1期107-110,共4页
Acta Academiae Medicinae Sinicae
